Literature DB >> 30693664

The 6q25.1 rs2046210 polymorphism is associated with an elevated susceptibility to breast cancer: A meta-analysis of 261,703 subjects.

Tie-Feng Jin1, Wen-Ting Zhang1, Zhen-Feng Zhou2.   

Abstract

BACKGROUND: Several genome-wide association studies already explored the associations between 6q25.1 rs2046210 polymorphism and breast cancer (BC), but the results of these studies were not consistent. Thus, we conducted a meta-analysis of relevant studies to better analyze the effects of rs2046210 polymorphism on individual susceptibility to BC.
METHODS: PubMed, Web of Science, and Embase were searched for eligible studies. Odds ratios (ORs) and 95% confidence intervals (CIs) were calculated.
RESULTS: Totally 21 studies with 261,703 subjects were analyzed. A significant association with BC was observed for the rs2046210 polymorphism in GG versus GA +AA (dominant comparison, p < 0.0001, OR = 0.78, 95% CI 0.73-0.83), AA versus GG + GA (recessive comparison, p < 0.0001, OR = 1.21, 95% CI 1.18-1.24), GA versus GG + AA (overdominant comparison, p < 0.0001, OR = 1.12, 95% CI 1.08-1.16), and G versus A (allele comparison, p < 0.0001, OR = 0.86, 95% CI 0.82-0.89). Further subgroup analyses yielded similar positive results in both Asians and Caucasians.
CONCLUSION: In summary, our findings suggested that the rs2046210 polymorphism may serve as a potential genetic biomarker of BC in both Asians and Caucasians.
© 2019 The Authors. Molecular Genetics & Genomic Medicine published by Wiley Periodicals, Inc.

Entities:  

Keywords:  6q25.1; breast cancer; meta-analysis; rs2046210 polymorphism

Mesh:

Year:  2019        PMID: 30693664      PMCID: PMC6418377          DOI: 10.1002/mgg3.553

Source DB:  PubMed          Journal:  Mol Genet Genomic Med        ISSN: 2324-9269            Impact factor:   2.183


INTRODUCTION

Breast cancer (BC) refers to malignancy that develops from epithelial tissue of breast. It is the second most common cancer globally, and the most frequent cancer among females (Siegel, Ma, Zou, & Jemal, 2014). In spite of rapid progress in chemotherapy and minimally invasive surgery achieved in the last few decades, BC still ranks as the fifth most common cause of cancer‐related deaths in both sexes, and the primary cause of cancer‐related deaths in women (Ferlay et al., 2015). Despite its high prevalence, the pathogenesis of BC is still not fully understood. Although obesity, hormone replacement therapy, and radiation were identified as potential risk factors of developing BC (Sun et al., 2017; Winters, Martin, Murphy, & Shokar, 2017), the fact that not everyone exposed to above‐mentioned carcinogenic factors ultimately develop BC suggests that inherited factors are also involved in the development of BC. Recently, a genome‐wide association study (GWAS) conducted by zheng et al found that the rs2046210 G/A polymorphism at 6q25.1 was significantly associated with an elevated susceptibility to BC in both Chinese and Europeans (Zheng et al., 2009). Since then, numerous genetic association studies were performed in diverse populations, with inconsistent results (Barzan et al., 2013; Dai et al., 2012; Garehdaghchi, Derakhshan, & Khaniani, 2016; Han et al., 2011). Therefore, we conducted a meta‐analysis of all relevant studies to better analyze the effects of rs2046210 polymorphism on individual susceptibility to BC.

MATERIAL AND METHODS

Literature search and inclusion criteria

The current meta‐analysis followed the Preferred Reporting Items for Systematic Reviews and Meta‐analyses (PRISMA) checklist (Moher, Liberati, Tetzlaff, Altman, & PRISMA group, 2009). PubMed, Web of Science, and Embase were searched for potentially eligible articles using the combination of following terms: “6q25.1,” “rs2046210,” “polymorphism,” “variant,” “variation,” “mutation,” “genotype,” “allele,” and “breast cancer.” We also reviewed the reference lists of all retrieved articles for other potentially eligible studies. To test the research hypothesis of this meta‐analysis, included studies should meet all the following criteria: (a) case–control study about rs2046210 polymorphism and BC; (b) providing sufficient data for calculating odds ratios (ORs) and 95% confidence intervals (CIs); (c) full text in English available. Studies were excluded if one of the following conditions was fulfilled: (a) not related to rs2046210 polymorphism and BC; (b) pedigree studies; (c) case reports or case series. In the case of duplicate reports by the same authors, we only included the most recent study.

Data extraction and quality assessment

We extracted the following information from eligible studies: (a) name of the first author; (b) year of publication; (c) country and ethnicity of participants; (d) sample size; and (e) the genotypic distribution of rs2046210 polymorphism in cases and controls. The probability value (p value) of Hardy–Weinberg equilibrium (HWE) was also calculated. We used the Newcastle–Ottawa scale (NOS) to evaluate the quality of eligible studies (Stang, 2010). The NOS has a score range of zero to nine, and studies with a score of more than seven were thought to be of high quality. Two reviewers conducted data extraction and quality assessment independently. When necessary, we wrote to the corresponding authors for extra information. Any disagreement between two reviewers was solved by discussion until a consensus was reached.

Statistical analyses

In the current study, we performed statistical analyses by using Review Manager Version 5.3.3. We calculated ORs and 95% CIs to estimate potential associations between rs2046210 polymorphism and BC in dominant (GG vs. GA + AA), recessive (AA vs. GG + GA), additive (GA vs. GG + AA) and allele (G vs. A) models, and a p value of 0.05 or less was defined as statistically significant. Between‐study heterogeneities were evaluated by I 2 statistic. Random‐effect models (REMs) would be used for analyses if I 2 was >50%. Otherwise, analyses would be conducted with fixed‐effect models (FEMs). Subgroup analyses were subsequently carried out by ethnicity. Stabilities of synthetic results were tested in sensitivity analyses. Publication biases were assessed by funnel plots.

RESULTS

Characteristics of included studies

We found 171 articles by using our searching strategy. After excluding irrelevant and duplicate articles, 29 articles were retrieved for further evaluation. Another eight articles were subsequently excluded after reading the full text. Ultimately, a total of 21 eligible studies involving 131,785 cases and 129,918 controls were enrolled for analyses (see Figure 1). Characteristics of included studies were shown in Table 1.
Figure 1

Flowchart of study selection for the present study

Table 1

The characteristics of included studies for rs2046210 polymorphism and breast cancer

First author, yearCountryEthnicitySample sizeGenotype distribution p‐Value for HWENOS score
CasesControls
Antoniou, 2011 UKCaucasian5,515/5,3022,067/2,669/7792,282/2,361/6590.2078
Barzan, 2013GermanyCaucasian311/960NANANA7
Barzan, 2013GermanyAsian984/2,206NANANA7
Cai, 2011 USACaucasian4,373/3,8851,689/2,097/5871,576/1,836/4730.0818
Cai, 2011 USAAsian11,996/9,7484,208/5,805/1,9834,161/4,384/1,2030.3588
Campa, 2011 GermanyCaucasian8,298/1,15433,322/3,796/1,1804,904/5,161/1,4780.0378
Chan, 2012 SingaporeAsian1,173/1,417369/573/231598/639/1800.6488
Dai, 2012ChinaAsian1,768/1,850582/873/313767/836/2470.4228
Garehdaghchi, 2016TurkeyCaucasian192/18656/105/3158/95/330.5838
Han, 2011KoreaAsian3,251/3,4931,260/1,565/4261586/1531/3760.8208
He, Liu, Chen, Sun, Liu, & Shao 2016 ChinaAsian254/33989/122/43139/144/560.0768
Hein, 2012 GermanyCaucasian54,298/40,90422,357/24,190/6,75121,823/21,751/5,5200.3668
Hein, 2012 GermanyAsian2,983/2,3341,041/1,455/4871,020/1,048/2660.8978
Huo, 2012 USAMixed1,509/1,383NANANA7
Jiang, 2011 ChinaAsian493/510NANANA7
Kim, 2012 KoreaAsian6,273/5,871NANANA7
Mulligan, 2011 UKCaucasian4,646/4,3521,732/2,255/6591,886/1,919/5470.0888
Ruiz‐Narváez , 2012 USAMixed1,191/1,941NANANA7
Stacey, 2010 IcelandCaucasian7,899/11,234NANANA7
Stacey, 2010 IcelandAsian1,126/1,118NANANA7
Stacey, 2010 IcelandMixed1,151/934NANANA7
Stevens, 2011 USAMixed27,07/1,385NANANA7
Wang, 2012 ChinaAsian1,062/1,072349/517/196447/475/1500.1898
Zheng, 2009 USAMixed810/1,784NANANA7
Zheng, 2009 USAAsian6,472/3,9622,162/3,208/1,1021,614/1,812/5360.4438
Zheng, 2009 USACaucasian1,591/1,466614/761/216617/690/1590.0988
Zhou, 2015 ChinaAsian459/549159/217/83223/252/740.8348

HWE: Hardy–Weinberg equilibrium; NA: Not available; NOS: Newcastle–Ottawa scale.

Flowchart of study selection for the present study The characteristics of included studies for rs2046210 polymorphism and breast cancer HWE: Hardy–Weinberg equilibrium; NA: Not available; NOS: Newcastle–Ottawa scale.

Overall and subgroup analyses

Totally 261,703 subjects were analyzed. A significant association with BC was observed for the rs2046210 polymorphism in GG versus GA + AA (dominant comparison, p < 0.0001, OR = 0.78, 95% CI 0.73–0.83), AA versus GG +GA (recessive comparison, p < 0.0001, OR = 1.21, 95% CI 1.18–1.24), GA versus GG + AA (overdominant comparison, p < 0.0001, OR = 1.12, 95% CI 1.08–1.16), and G versus A (allele comparison, p < 0.0001, OR = 0.86, 95% CI 0.82–0.89). Further subgroup analyses yielded similar positive results in both Asians and Caucasians (see Table 2).
Table 2

Results of overall and subgroup analyses for rs2046210 polymorphism and breast cancer

PopulationSample sizeDominant comparisonRecessive comparisonOverdominant comparisonAllele comparison
p ValueOR (95% CI) I 2 statistic p Value OR(95% CI) I 2 statistic p ValueOR (95% CI) I 2 statistic p ValueOR (95% CI) I 2 statistic
Overall131,785/129,918 <0.0001 0.78 (0.73–0.83) 88% <0.0001 1.21 (1.18–1.24) 72% <0.0001 1.12 (1.08–1.16) 62% <0.0001 0.86 (0.82–0.89) 89%
Asian38,294/34,469 <0.0001 0.72 (0.70–0.75) 0% <0.0001 1.39 (1.32–1.46) 13% <0.0001 1.16 (1.12–1.20) 0% <0.0001 0.79 (0.73–0.84) 87%
Caucasian86,123/88,022 <0.0001 0.86 (0.82–0.91) 71% <0.0001 1.14 (1.11–1.18) 0% 0.001 1.08 (1.03–1.14) 64% <0.0001 0.91 (0.88–0.94) 64%

CI: Confidence interval; NA: Not available; OR: Odds ratio.

The values in bold represent there are statistically significant differences between cases and controls.

Results of overall and subgroup analyses for rs2046210 polymorphism and breast cancer CI: Confidence interval; NA: Not available; OR: Odds ratio. The values in bold represent there are statistically significant differences between cases and controls.

Sensitivity analyses

We conducted sensitivity analyses by eliminating one individual study each time. The significant associations detected in pooled analyses remained unchanged in all comparisons, which suggested that our findings were statistically stable.

Publication biases

We used funnel plots to evaluate potential publication biases. The shape of funnel plots was symmetry for every comparison, which indicated that severe publication biases were unlikely.

DISCUSSION

To the best of our knowledge, this is so far the most comprehensive meta‐analysis about rs2046210 polymorphism and BC. The pooled analyses revealed that the rs2046210 polymorphism was significantly associated with BC in both Asians and Caucasians. The stabilities of synthetic results were evaluated by sensitivity analyses, and no alterations of results were observed in any comparisons, which suggested that our findings were statistically stable. As for evaluation of heterogeneities, significant heterogeneities were detected in every comparison of overall analyses, and thus all analyses were performed with REMs. But in further subgroup analyses, a reduction tendency of heterogeneity was found for Asians, which suggested that differences in ethnicity could partially explain observed heterogeneities between studies. There are several points that worth noting about this meta‐analysis. Firstly, the 6q25.1 rs2046210 polymorphism is located within 1‐Mb upstream of ESR1, the encoder of ERα. Since it was evident the binding of estrogen and ERα could result in increased proliferation of normal and cancerous breast epithelial cells (Ali & Coombes, 2000; Russo & Russo, 2006), it is possible that rs2046210 polymorphism may alter the expression level of ESR1 and consequentially influence individual susceptibility to BC. Secondly, the etiology of BC is extremely complex, and as a consequence, to better elucidate potential roles of genetic variations in BC, we strongly recommend future studies to conduct haplotype analyses and investigate potential gene–gene interactions. Some limitations of this meta‐analysis should also be noted when interpreting our findings. First, our pooled analyses were based on unadjusted estimations due to lack of raw data, but we have to admit that failure to perform further adjusted analyses may impact the reliability of our findings (Xie, Shi, & Liu, 2017). Second, heterogeneities between studies remained significant in certain subgroup comparisons, especially for Caucasians, which suggested that the inconsistent results of included studies could not be fully attributed to ethnicity, and differences in other unmeasured characteristics of participants may also contribute to heterogeneities (Shi, Xie, Jia, & Li, 2016). Third, associations between rs2046210 polymorphism and BC may also be modified by gene–gene and gene–environmental interactions. However, most studies did not consider these potential interactions, which impeded us to conduct relevant analyses (Shi et al., 2015). Considering the above‐mentioned limitations, our findings should be interpreted with caution.

CONCLUSIONS

In summary, our meta‐analysis suggested that the rs2046210 polymorphism may serve as a potential genetic biomarker of BC in both Asians and Caucasians. However, further well‐designed studies are still needed to confirm our findings.

INFORMED CONSENT

For this type of study formal consent is not required.

ETHICAL APPROVAL

This article does not contain any studies with human participants or animals performed by any of the authors.

CONFLICT OF INTEREST

The authors declare that they have no conflict of interest.

AUTHORS' CONTRIBUTIONS

Tie‐feng Jin and Zhen‐feng Zhou conceived of the study, participated in its design. Tie‐feng Jin and Wen‐ting Zhang conducted the systematic literature review. Tie‐feng Jin and Wen‐ting Zhang performed data analyses. Tie‐feng Jin and Zhen‐feng Zhou drafted the manuscript. All authors have read and approved the final manuscript.
  31 in total

1.  Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement.

Authors:  David Moher; Alessandro Liberati; Jennifer Tetzlaff; Douglas G Altman
Journal:  Ann Intern Med       Date:  2009-07-20       Impact factor: 25.391

2.  Cancer statistics, 2014.

Authors:  Rebecca Siegel; Jiemin Ma; Zhaohui Zou; Ahmedin Jemal
Journal:  CA Cancer J Clin       Date:  2014-01-07       Impact factor: 508.702

Review 3.  Breast Cancer Epidemiology, Prevention, and Screening.

Authors:  Stella Winters; Charmaine Martin; Daniel Murphy; Navkiran K Shokar
Journal:  Prog Mol Biol Transl Sci       Date:  2017-10-10       Impact factor: 3.622

4.  Association of common genetic variants with breast cancer risk and clinicopathological characteristics in a Chinese population.

Authors:  M Chan; S M Ji; C S Liaw; Y S Yap; H Y Law; C S Yoon; C Y Wong; W S Yong; N S Wong; R Ng; K W Ong; P Madhukumar; C L Oey; P H Tan; H H Li; P Ang; G H Ho; A S G Lee
Journal:  Breast Cancer Res Treat       Date:  2012-09-11       Impact factor: 4.872

5.  A genome-wide association study identifies a breast cancer risk variant in ERBB4 at 2q34: results from the Seoul Breast Cancer Study.

Authors:  Hyung-cheol Kim; Ji-Young Lee; Hyuna Sung; Ji-Yeob Choi; Sue K Park; Kyoung-Mu Lee; Young Jin Kim; Min Jin Go; Lian Li; Yoon Shin Cho; Miey Park; Dong-Joon Kim; Ji Hee Oh; Jun-Woo Kim; Jae-Pil Jeon; Soon-Young Jeon; Haesook Min; Hyo Mi Kim; Jaekyung Park; Keun-Young Yoo; Dong-Young Noh; Sei-Hyun Ahn; Min Hyuk Lee; Sung-Won Kim; Jong Won Lee; Byeong-Woo Park; Woong-Yang Park; Eun-Hye Kim; Mi Kyung Kim; Wonshik Han; Sang-Ah Lee; Keitaro Matsuo; Chen-Yang Shen; Pei-Ei Wu; Chia-Ni Hsiung; Jong-Young Lee; Hyung-Lae Kim; Bok-Ghee Han; Daehee Kang
Journal:  Breast Cancer Res       Date:  2012-03-27       Impact factor: 6.466

6.  Breast cancer risk assessment with five independent genetic variants and two risk factors in Chinese women.

Authors:  Juncheng Dai; Zhibin Hu; Yue Jiang; Hao Shen; Jing Dong; Hongxia Ma; Hongbing Shen
Journal:  Breast Cancer Res       Date:  2012-01-23       Impact factor: 6.466

7.  Matrix Metalloproteinase-2 Polymorphisms and Incident Coronary Artery Disease: A Meta-Analysis.

Authors:  Yujie Shi; Jian Zhang; Chen Tan; Wei Xu; Qi Sun; Junxia Li
Journal:  Medicine (Baltimore)       Date:  2015-07       Impact factor: 1.889

8.  Evaluation of functional genetic variants at 6q25.1 and risk of breast cancer in a Chinese population.

Authors:  Yanru Wang; Yisha He; Zhenzhen Qin; Yue Jiang; Guangfu Jin; Hongxia Ma; Juncheng Dai; Jiaping Chen; Zhibin Hu; Xiaoxiang Guan; Hongbing Shen
Journal:  Breast Cancer Res       Date:  2014-08-14       Impact factor: 6.466

9.  Comparison of 6q25 breast cancer hits from Asian and European Genome Wide Association Studies in the Breast Cancer Association Consortium (BCAC).

Authors:  Rebecca Hein; Melanie Maranian; John L Hopper; Miroslaw K Kapuscinski; Melissa C Southey; Daniel J Park; Marjanka K Schmidt; Annegien Broeks; Frans B L Hogervorst; H Bas Bueno-de-Mesquita; H Bas Bueno-de-Mesquit; Kenneth R Muir; Artitaya Lophatananon; Suthee Rattanamongkongul; Puttisak Puttawibul; Peter A Fasching; Alexander Hein; Arif B Ekici; Matthias W Beckmann; Olivia Fletcher; Nichola Johnson; Isabel dos Santos Silva; Julian Peto; Elinor Sawyer; Ian Tomlinson; Michael Kerin; Nicola Miller; Frederick Marmee; Andreas Schneeweiss; Christof Sohn; Barbara Burwinkel; Pascal Guénel; Emilie Cordina-Duverger; Florence Menegaux; Thérèse Truong; Stig E Bojesen; Børge G Nordestgaard; Henrik Flyger; Roger L Milne; Jose Ignacio Arias Perez; M Pilar Zamora; Javier Benítez; Hoda Anton-Culver; Argyrios Ziogas; Leslie Bernstein; Christina A Clarke; Hermann Brenner; Heiko Müller; Volker Arndt; Christa Stegmaier; Nazneen Rahman; Sheila Seal; Clare Turnbull; Anthony Renwick; Alfons Meindl; Sarah Schott; Claus R Bartram; Rita K Schmutzler; Hiltrud Brauch; Ute Hamann; Yon-Dschun Ko; Shan Wang-Gohrke; Thilo Dörk; Peter Schürmann; Johann H Karstens; Peter Hillemanns; Heli Nevanlinna; Tuomas Heikkinen; Kristiina Aittomäki; Carl Blomqvist; Natalia V Bogdanova; Iosif V Zalutsky; Natalia N Antonenkova; Marina Bermisheva; Darya Prokovieva; Albina Farahtdinova; Elza Khusnutdinova; Annika Lindblom; Sara Margolin; Arto Mannermaa; Vesa Kataja; Veli-Matti Kosma; Jaana Hartikainen; Xiaoqing Chen; Jonathan Beesley; Diether Lambrechts; Hui Zhao; Patrick Neven; Hans Wildiers; Stefan Nickels; Dieter Flesch-Janys; Paolo Radice; Paolo Peterlongo; Siranoush Manoukian; Monica Barile; Fergus J Couch; Janet E Olson; Xianshu Wang; Zachary Fredericksen; Graham G Giles; Laura Baglietto; Catriona A McLean; Gianluca Severi; Kenneth Offit; Mark Robson; Mia M Gaudet; Joseph Vijai; Grethe Grenaker Alnæs; Vessela Kristensen; Anne-Lise Børresen-Dale; Esther M John; Alexander Miron; Robert Winqvist; Katri Pylkäs; Arja Jukkola-Vuorinen; Mervi Grip; Irene L Andrulis; Julia A Knight; Gord Glendon; Anna Marie Mulligan; Jonine D Figueroa; Montserrat García-Closas; Jolanta Lissowska; Mark E Sherman; Maartje Hooning; John W M Martens; Caroline Seynaeve; Margriet Collée; Per Hall; Keith Humpreys; Kamila Czene; Jianjun Liu; Angela Cox; Ian W Brock; Simon S Cross; Malcolm W R Reed; Shahana Ahmed; Maya Ghoussaini; Paul D P Pharoah; Daehee Kang; Keun-Young Yoo; Dong-Young Noh; Anna Jakubowska; Katarzyna Jaworska; Katarzyna Durda; Elżbieta Złowocka; Suleeporn Sangrajrang; Valerie Gaborieau; Paul Brennan; James McKay; Chen-Yang Shen; Jyh-Cherng Yu; Huan-Ming Hsu; Ming-Feng Hou; Nick Orr; Minouk Schoemaker; Alan Ashworth; Anthony Swerdlow; Amy Trentham-Dietz; Polly A Newcomb; Linda Titus; Kathleen M Egan; Georgia Chenevix-Trench; Antonis C Antoniou; Manjeet K Humphreys; Jonathan Morrison; Jenny Chang-Claude; Douglas F Easton; Alison M Dunning
Journal:  PLoS One       Date:  2012-08-07       Impact factor: 3.240

10.  Evaluation of a newly discovered breast cancer susceptibility locus at 6q25.1 in Iranian Azari-Turkish women.

Authors:  Ziba Garehdaghchi; Siam Mansoori Derakhshan; Mahmoud Shekari Khaniani
Journal:  Contemp Oncol (Pozn)       Date:  2016-09-05
View more
  1 in total

1.  Association of Estrogen-Related Polygenetic Risk Scores with Breast Cancer and Interactions with Alcohol Intake, Early Menarche, and Nulligravida.

Authors:  Sang Shin Song; Suna Kang; Sunmin Park
Journal:  Asian Pac J Cancer Prev       Date:  2022-01-01
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.